BCAX
Bicara Therapeutics Inc. Common Stock
Biotechnology
Market Cap$1.26B
5Y Perf.-11.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BCAX vs ERAS
Revenue, margins, valuation, and 5-year total return — side by side.
ERAS
Erasca, Inc.
Biotechnology
Market Cap$2.95B
5Y Perf.+270.7%
BCAX vs ERAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCAX | ERAS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.26B | $2.95B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-122M | $-128M |
| Total Debt | $738K | $52M |
| Cash & Equiv. | $490M | $68M |
BCAX vs ERAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCAX
ERAS
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Bicara Therapeutics… (BCAX) | 100 | 88.7 | -11.3% |
| Erasca, Inc. (ERAS) | 100 | 370.7 | +270.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCAX vs ERAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ERAS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Bicara Therapeutics Inc. Common Stock is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BCAX
Bicara Therapeutics Inc. Common Stock
The Long-Run Compounder
BCAX is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -1.4% 10Y total return vs ERAS's -40.3%
- Lower volatility, beta 1.79, Low D/E 0.1%, current ratio 27.93x
- -28.6% ROA vs ERAS's -30.4%, ROIC -21.3% vs -39.2%
Best for: long-term compounding and sleep-well-at-night
ERAS
Erasca, Inc.
The Income Pick
ERAS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.78
- EPS growth 16.9%
- Beta 0.78, current ratio 9.84x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ERAS | 19.8% revenue growth vs BCAX's -104.3% |
| Quality / Margins | ERAS | 4.0% margin vs BCAX's 2.6% |
| Stability / Safety | ERAS | Beta 0.78 vs BCAX's 1.79 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ERAS | +7.5% vs BCAX's +94.2% |
| Efficiency (ROA) | BCAX | -28.6% ROA vs ERAS's -30.4%, ROIC -21.3% vs -39.2% |
BCAX vs ERAS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBCAXLAGGINGERAS
ERASErasca, Inc.
2leads
BCAXBicara Therapeutics I…
2leads
6 Total Categories
CATEGORYLEADERvs ERASMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ERAS1/1
Valuation MetricsMultiples, price ratios, and targets
BCAX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BCAX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ERAS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ERAS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BCAX and ERAS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$141M | -$141M |
| Net IncomeAfter-tax profit | -$122M | -$128M |
| Free Cash FlowCash after capex | -$113M | -$98M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -109.4% | 0.0% |
ERAS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BCAX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| Market CapShares × price | $1.3B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $772M | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | -18.47x | -15.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.55x | 5.74x |
| Price / FCFMarket cap ÷ FCF | — | — |
BCAX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
BCAX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BCAX delivers a -30.2% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-37 for ERAS. BCAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ERAS's 0.12x. On the Piotroski fundamental quality scale (0–9), BCAX scores 3/9 vs ERAS's 2/9, reflecting mixed financial health.
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -30.2% | -36.7% |
| ROA (TTM)Return on assets | -28.6% | -30.4% |
| ROICReturn on invested capital | -21.3% | -39.2% |
| ROCEReturn on capital employed | -21.4% | -42.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.12x |
| Net DebtTotal debt minus cash | -$489M | -$16M |
| Cash & Equiv.Liquid assets | $490M | $68M |
| Total DebtShort + long-term debt | $738,000 | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
BCAX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ERAS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BCAX five years ago would be worth $9,863 today (with dividends reinvested), compared to $5,967 for ERAS. Over the past 12 months, ERAS leads with a +745.5% total return vs BCAX's +94.2%. The 3-year compound annual growth rate (CAGR) favors ERAS at 53.8% vs BCAX's -0.5% — a key indicator of consistent wealth creation.
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +41.0% | +189.7% |
| 1-Year ReturnPast 12 months | +94.2% | +745.5% |
| 3-Year ReturnCumulative with dividends | -1.4% | +263.6% |
| 5-Year ReturnCumulative with dividends | -1.4% | -40.3% |
| 10-Year ReturnCumulative with dividends | -1.4% | -40.3% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +53.8% |
ERAS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BCAX and ERAS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ERAS is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than BCAX's 1.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BCAX currently trades 95.2% from its 52-week high vs ERAS's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 0.62x |
| 52-Week HighHighest price in past year | $24.25 | $24.28 |
| 52-Week LowLowest price in past year | $7.80 | $1.06 |
| % of 52W HighCurrent price vs 52-week peak | +95.2% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 64.4 | 36.9 |
| Avg Volume (50D)Average daily shares traded | 522K | 7.0M |
Evenly matched — BCAX and ERAS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BCAX as "Buy" and ERAS as "Buy". Consensus price targets imply 30.8% upside for ERAS (target: $14) vs -13.4% for BCAX (target: $20).
| Metric | BCAXBicara Therapeuti… | ERASErasca, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | $13.60 |
| # AnalystsCovering analysts | 6 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ERAS leads in 2 of 6 categories (Income & Cash Flow, Total Returns). BCAX leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallBicara Therapeutics Inc. Co… (BCAX)Leads 2 of 6 categories
Loading custom metrics...
BCAX vs ERAS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BCAX or ERAS a better buy right now?
Analysts rate Bicara Therapeutics Inc.
Common Stock (BCAX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCAX or ERAS?
Over the past 5 years, Bicara Therapeutics Inc.
Common Stock (BCAX) delivered a total return of -1. 4%, compared to -40. 3% for Erasca, Inc. (ERAS). Over 10 years, the gap is even starker: BCAX returned -3. 5% versus ERAS's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCAX or ERAS?
By beta (market sensitivity over 5 years), Erasca, Inc.
(ERAS) is the lower-risk stock at 0. 62β versus Bicara Therapeutics Inc. Common Stock's 1. 72β — meaning BCAX is approximately 178% more volatile than ERAS relative to the S&P 500. On balance sheet safety, Bicara Therapeutics Inc. Common Stock (BCAX) carries a lower debt/equity ratio of 0% versus 12% for Erasca, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BCAX or ERAS?
On earnings-per-share growth, the picture is similar: Erasca, Inc.
grew EPS 16. 9% year-over-year, compared to -25. 0% for Bicara Therapeutics Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCAX or ERAS?
Bicara Therapeutics Inc.
Common Stock (BCAX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Erasca, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCAX leads at 0. 0% versus 0. 0% for ERAS. At the gross margin level — before operating expenses — BCAX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BCAX or ERAS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BCAX or ERAS better for a retirement portfolio?
For long-horizon retirement investors, Erasca, Inc.
(ERAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62)). Bicara Therapeutics Inc. Common Stock (BCAX) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ERAS: -41. 9%, BCAX: -3. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BCAX and ERAS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.